aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
jueves, 29 de febrero de 2024
Disparities in racial, ethnic, and payer groups for pediatric safety events in US hospitals. February 28, 2024
https://psnet.ahrq.gov/issue/disparities-racial-ethnic-and-payer-groups-pediatric-safety-events-us-hospitals
Disparities in racial, ethnic, and payer groups for pediatric safety events in US hospitals.
Parikh K, Hall M, Tieder JS, et al. Pediatrics. 2024;Epub Feb 12.
Disparities in healthcare are emerging as a core patient safety issue. This population-based retrospective study examined disparities in the AHRQ pediatric safety indicators (PDIs). The findings indicate that Black and Hispanic pediatric patients have a higher risk of safety events (particularly sepsis and postoperative respiratory failure) compared to white patients. Findings were similar when comparing patients with Medicaid versus private insurance.
Emergency department volume and delayed diagnosis of serious pediatric conditions. February 28, 2024
https://psnet.ahrq.gov/issue/emergency-department-volume-and-delayed-diagnosis-serious-pediatric-conditions
Emergency department volume and delayed diagnosis of serious pediatric conditions.
Michelson KA, Rees CA, Florin TA, et al. JAMA Pediatr. 2024;Epub Feb 12.
Diagnostic delays in the emergency department (ED) are a serious patient safety concern. This retrospective cohort study included children treated at 954 EDs across 8 states, and examined the association between ED volume and delayed diagnosis of first-time diagnosis of an acute, serious conditions (e.g., bacterial meningitis, compartment syndrome, stroke). The researchers found that EDs with lower pediatric volume had higher rates of delayed diagnosis across 23 serious conditions.
Exploring clinical lessons learned by experienced hospitalists from diagnostic errors and successes. February 28, 2024
https://psnet.ahrq.gov/issue/exploring-clinical-lessons-learned-experienced-hospitalists-diagnostic-errors-and-successes
Exploring clinical lessons learned by experienced hospitalists from diagnostic errors and successes.
Kotwal S, Howell M, Zwaan L, et al. J Gen Intern Med. 2024;Epub Jan 26.
Achieving diagnostic excellence is a primary focus in health care. In this qualitative study, researchers interviewed hospitalists at five hospitals to examine clinical lessons learned from diagnostic errors and successes. Five themes were identified: excellence in clinical reasoning as a core skill; elucidating insights from patients and other care team members; reflecting on the diagnostic process; commitment to a growth mindset; and prioritizing self-care and well-being.
Virtual Public Workshop – Accreditation Scheme for Conformity Assessment Expansion - April 17, 2024 APRIL 17, 2024 +++
https://www.fda.gov/medical-devices/medical-devices-news-and-events/virtual-public-workshop-accreditation-scheme-conformity-assessment-expansion-april-17-2024-04172024?utm_medium=email&utm_source=govdelivery
CDRHNew - News and Updates
https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrhnew-news-and-updates
LEADER 3D: Learning and Education to Advance and Empower Rare Disease Drug Developers
PUBLIC REPORT OF EXTERNAL STAKEHOLDER ANALYSIS
https://www.fda.gov/media/176557/download?attachment=&utm_medium=email&utm_source=govdelivery
Now Available: LEADER 3D Public Report of External Engagement Analysis
As we observe Rare Disease Week 2024, CDER is pleased to announce the release of the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) Public Report of External Stakeholder Analysis.
The Accelerating Rare disease Cures (ARC) Program initiated LEADER 3D to better understand the unique challenges in bringing rare disease products to market, such as challenges related to nonclinical studies, dose-finding, natural history studies and registries, novel endpoint and biomarker development, clinical trial design and analysis, and regulatory considerations.
As part of LEADER 3D, CDER’s Rare Diseases Team worked with an independent contractor to conduct interviews with the rare disease drug development community and performed a review of public docket comments to identify educational opportunities across topics of interest in rare disease drug development. This new report summarizes findings from the analysis of these interactions and provides recommendations for continued efforts to expand outreach and education for those involved in rare disease drug development.
We want to thank the rare disease drug development community for their continued engagement in achieving the ARC Program mission to accelerate the availability of drug and biologic products for patients with rare diseases.
miércoles, 28 de febrero de 2024
Upcoming Event - Attend the USPTO’s first Public Engagement Partnership meeting
https://www.uspto.gov/about-us/events/attend-public-engagement-partnership-meeting?utm_medium=email&utm_source=govdelivery
Join the United States Patent and Trademark Office (USPTO) virtually or in person on March 1 from 1-5 p.m. ET at the USPTO headquarters in Alexandria, Virginia for the first meeting of their Public Engagement Partnership series, which may be of interest to patients, caregivers and patient advocates.
The meeting will provide foundational education about the patenting process and the USPTO’s practices and policies, and include a panel discussion on public interest community viewpoints on the patent system.
For questions or comments, please email PublicEngagementPartnership@uspto.gov.
Virtual Public Workshop – Accreditation Scheme for Conformity Assessment Expansion - April 17, 2024 APRIL 17, 2024
https://www.fda.gov/medical-devices/medical-devices-news-and-events/virtual-public-workshop-accreditation-scheme-conformity-assessment-expansion-april-17-2024-04172024?utm_medium=email&utm_source=govdelivery
The purpose of this workshop is for the FDA to engage with stakeholders about potentially expanding the ASCA program, which is designed to streamline conformity assessment aspects of medical device regulatory review.
Workshop Date: Wednesday, April 17, 2024, from 11:00 am - 1:00 pm ET.
Location: Virtual
Registration Deadline: Tuesday, April 16, 2024, by 4:00 pm ET.
Evidence Map on Home and Community-Based Services
Evidence Map on Home and Community-Based Services: This Technical Brief provides an evidence map that summarizes service categories of HCBS and describes the research on the interventions and populations have been studied and quality measures proposed for HCBS. This Technical Brief also identifies gaps in the evidence base.
2024 Summer Intramural Fellowship Program - Apply by March 8 for AHRQ’s 2024 Summer Intramural Fellowship Program
2024 Summer Intramural Fellowship Program: The AHRQ Intramural Fellowship Program provides opportunities for individuals to work with leading health services researchers in the conduct and support of research on "real life" issues that support the Agency’s mission and contributes to improvements in health care.
March 13 Webinar Will Explore How Patient Stories Can Improve Care
https://hrsa-gov.zoomgov.com/webinar/register/WN_M2w642qMRliQxw8ip3eTZQ?utm_campaign=enews20240201&utm_medium=email&utm_source=govdelivery#/registration
Register now for a webinar on March 13 from 2 to 4 p.m. ET about how healthcare providers and staff can engage with patients and use their stories to provide better and safer care. The event, part of Patient Safety Awareness Week, is sponsored by the Health Resources and Services Administration and co-hosted by federal partners including AHRQ, the Centers for Disease Control and Prevention, the Centers for Medicare & Medicaid Services, the Indian Health Service and the National Institutes of Health. Jay Baruch, M.D., a practicing emergency physician and award-winning author, lecturer and medical educator, will be the guest speaker.
TeamSTEPPS 3.0
TeamSTEPPS 3.0: TeamSTEPPS is an evidence-based set of teamwork tools, aimed at optimizing patient outcomes by improving communication and teamwork skills among health care professionals. The training provides guides, videos, and exercises to practice the skills.
Risk of bleeding with concomitant use of oral anticoagulants and aspirin: A systematic review and meta-analysis
https://pubmed.ncbi.nlm.nih.gov/38263263/
Patients are at higher risk of excessive bleeding when taking both blood thinners and aspirin together, according to an AHRQ-funded study published in American Journal of Health-System Pharmacy. Researchers reviewed 42 published studies and found that patients who took both oral anticoagulant medications (which are blood thinners such as warfarin) and aspirin had a higher chance of bleeding compared with those only taking blood thinners. Warfarin is prescribed for stroke prevention in atrial fibrillation and for treatment and secondary prevention of venous thromboembolism, while aspirin may still be used to prevent primary cardiovascular events among high-risk patients.
(Source: AHRQ 2023 National Healthcare Quality and Disparities Report.)
https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/2023-nhqdr.pdf#page=62
The number of people working in ambulatory settings of the healthcare sector increased by 5.7 percent between January 2020 and January 2023. In the same timeframe, the number of workers employed by nursing homes and residential care facilities decreased by 8.4 percent.
martes, 27 de febrero de 2024
Optimal Medical Treatments for Non-Metastatic Gastric Cancers
Optimal Medical Treatments for Non-Metastatic Gastric Cancers: AHRQ will conduct an evidence-based review to inform a clinical practice guideline that addresses these uncertainties and will aid in reducing practice variation in the treatment of this disease. This will give clinicians, particularly medical oncologists in community practice, evidence-based guidance for the treatment of this disease.
Evidence Map on Home and Community-Based Services
Evidence Map on Home and Community-Based Services: This Technical Brief provides an evidence map that summarizes service categories of HCBS and describes the research on the interventions and populations have been studied and quality measures proposed for HCBS. This Technical Brief also identifies gaps in the evidence base.
Diagnosis and Treatment of Tethered Spinal Cord
Diagnosis and Treatment of Tethered Spinal Cord: The review summarizes the evidence regarding diagnosis, prophylactic treatment, symptomatic treatment, and repeat surgery of tethered spinal cord. With funding from the Patient Centered Outcomes Research Institute (PCORI), the Agency for Healthcare Research and Quality (AHRQ), commissioned this work to synthesize the findings on the diagnosis and treatment of tethered spinal cord. The systematic review aims to support the Congress for Neurological Surgeons (CNS) clinical practice guidelines.
a todos los que me siguen... a todos los que me leen... a todos los que me buscan... a todos...
A TODOS: el día 16 de febrero, luego de una brutal tormenta, se cortó internet, se cortaron las líneas telefónicas, por ende no hubo Wi-Fi, ni conexiones de ninguna índole… me llevó dos días entender dónde estaba el problema, ya que muchos vecinos del barrio, estaban en las mismas condiciones… acudí a Telecom Personal y también lo hice a Personal Telecom, ya que no sé dónde comienza una empresa y donde termina la otra… te ofrecen un teléfono que te indica que tienes que marcar 1, o bien, marcar 2, o bien, marcar 3, o bien marcar 4, o bien, marcar 5, o bien marcar 6, pero en algún momento serás atendido por alguien, a quien jamás verás… luego de variar por la escala, alguien atendió… dijo que el cable que conecta al barrio es viejo… dijo que ahora hay una novedosa fibra óptica, que curiosamente, también es un cable, pero nuevo… dijo que el costo del cambio era importante… dijo que había que consultar al servicio técnico… dijo muchas cosas que no recuerdo, porque fueron demasiadas… dijo que tal vez el día 27 de febrero harían una visita para ver de qué se trata… dijo que el costo actual era escaso y que al ser todo nuevo, debía aumentar, casi al doble, poco más, seguramente… dijo que había beneficios suculentos, y otros no tanto… dijo, y también dijo, y volvió a repetir, por si no se entendió… a nadie le importó que no hubiese servicio durante largos días… según dijeron, todo se compensa en la factura, lo cual está por verse… como sea, los días pasan y no hay teléfono, no hay internet, no hay Wi-Fi, no hay conexión alguna… los blog´s han quedado inaccesibles, sin actualizar, pero a nadie le importa… no me he tomado vacaciones porque no hay dónde ir, ya que la mayoría de las rutas están cortadas, por lluvias recurrentes y tormentas consecuentes… tampoco he salido de la casa porque la misma no puede quedar sola, ya que hay vigías que marcan la casa, y luego roban, sin que nadie haga nada… además, una casa sola es pasible de ser ocupada por indeseables asociados al poder del narcotráfico, que es socio del poder político… el estado dejó de existir hace dos meses y medio, gracias a la nueva administración anarcocapitalista, es decir, primero instala la anarquía donde antes hubo un estado de derecho, luego habla de capitalismo para los amigos del poder, que se apoderan de todo y someten a los mortales a sus designios… en definitiva, nos hemos quedado sin país, ya que cada uno está librado a su suerte… no hay garantías constitucionales… no hay a quien quejarse… no hay a quien reclamar (por nada)… no hay derechos ni humanos ni ciudadanos… la legislatura ha dejado de existir, porque muchos se han vendido a la nueva administración… mientras tanto, la justicia tampoco existe porque es inaccesible… y en el poder ejecutivo se ha instalado la demencia… la sociedad argentina está sucumbiendo a la estupidez humana de la clase política reinante… dentro de poco tiempo, nuestro país, pasará a ser una entelequia… por favor, tenelo en cuenta, porque no sé qué será de nosotros… el editor…
PD: y esto recién comienza… lo de internet es sólo una muestra…
PD2: gracias al equipo técnico de Telecom Personal… es necesario agradecer a los mortales que trabajan, como lo hizo uno…
viernes, 16 de febrero de 2024
Webinar Series: Strengthening Primary Care Research March 7 from 2:00-3:15 PM ET
Webinar Series: Strengthening Primary Care Research: This series of webinars focuses on how to strengthen AHRQ’s primary research. For recordings of the presentations and slides, reference the webinars.
National Center for Excellence in Primary Care Research
National Center for Excellence in Primary Care Research: AHRQ’s research to advance primary care infrastructure, delivery and outcomes. The National Center for Excellence in Primary Care Research (NCEPCR) is the intellectual home for primary care research at AHRQ. The NCEPCR is focused on the Nation's primary care system, providing evidence, practical tools, and other resources for researchers and evaluators, clinicians and clinical teams, quality improvement experts, and healthcare decision makers to improve the quality and safety of care. The NCEPCR is committed to listening to and learning from all members of the primary care community, including patients and families.
Making Patients Part of the Conversation: Integrating Patient-Generated Health Data into Care
https://digital.ahrq.gov/ahrq-funded-projects/search?f%5B0%5D=health_care_topic%3A8006&f%5B1%5D=technology%3A9031
Patient-generated health data (PGHD) helps providers understand the unique patient perspective. Unfortunately, there is often a gap between collection of PGHD and integration into patient care. Below is a sample of DHR projects that focus on understanding ways to effectively integrate and use this critical information to improve patient care and treatment.
To access our full portfolio of research on developing and assessing solutions for the collection and use of PGHD, visit AHRQ Funded Projects
jueves, 15 de febrero de 2024
SAMHSA’s GAINS Center Webinar: Planning for the Future: Ensuring Sustainability for Drug Treatment Courts Thursday, February 29, 1:30 – 3 p.m. ET
https://us06web.zoom.us/webinar/register/WN_pjZ9ovHYRM6_g8pF9Nnssg?utm_source=SAMHSA&utm_campaign=d6145a2ff6-EMAIL_CAMPAIGN_2024_02_14_07_17&utm_medium=email&utm_term=0_-d6145a2ff6-%5BLIST_EMAIL_ID%5D#/registration
Ensuring long-term sustainability for drug treatment courts requires careful planning of strategies that encompass data collection, messaging, and partnership building. In the aftermath of the COVID-19 pandemic, drug treatment courts have an opportunity to reexamine the focus of their programs on individuals in their communities identified as having high service needs and being at high risk of recidivism, who would benefit from intensive programming, such as a drug court. This means that courts may serve fewer individuals but still provide compelling benefits to system partners through reductions in calls to 911, law enforcement contacts, jail bookings, jail bed days, court hearings, and other costly interactions with criminal justice and behavioral health agencies, as well as priceless outcomes for community members through supported recovery for people with serious substance use disorders, reunited families, and restored hope.
This SAMHSA-funded GAINS Center webinar will discuss how drug treatment courts can plan for long-term sustainability through a multifaceted approach. The audience will hear about strategies that can be used by drug courts to ensure longevity, including ways to structure and organize a program for long-term success, strategies to increase support from partners and the community, and opportunities to secure ongoing funding.
SOPS Medical Office Database
SOPS Medical Office Database: The Medical Office SOPS Database is a central repository for survey data from medical offices that administered the AHRQ patient safety culture survey.
National Center for Excellence in Primary Care Research
National Center for Excellence in Primary Care Research: AHRQ’s research to advance primary care infrastructure, delivery and outcomes. The National Center for Excellence in Primary Care Research (NCEPCR) is the intellectual home for primary care research at AHRQ. The NCEPCR is focused on the Nation's primary care system, providing evidence, practical tools, and other resources for researchers and evaluators, clinicians and clinical teams, quality improvement experts, and healthcare decision makers to improve the quality and safety of care. The NCEPCR is committed to listening to and learning from all members of the primary care community, including patients and families.
Mapping AHRQ's 30-Year Investment in Primary Care Research (1990-2020)
Mapping AHRQ's 30-Year Investment in Primary Care Research (1990-2020): This report describes three decades (1990–2020) of AHRQ's primary care research and highlights how that research has impacted delivery of primary care. It details AHRQ's steady investment in research to improve primary care organization, workforce, quality and safety, digital healthcare, finance and cost, and prevention.
Eastern Virginia Medical School Uses, Contributes to AHRQ's Healthcare Simulation Dictionary
Eastern Virginia Medical School Uses, Contributes to AHRQ's Healthcare Simulation Dictionary: Eastern Virginia Medical School (EVMS) in Norfolk, Virginia, uses and contributes to the AHRQ Healthcare Simulation Dictionary, which international simulation experts developed to standardize the growing list of terms in this expanding field. AHRQ partnered with the Society for Simulation in Healthcare to develop the dictionary in order to boost communication and clarity in healthcare teaching, education, assessment, and research.
New Eligibility Rules Are a Financial Salve for Nearly 2 Million on Medi-Cal ++++
https://californiahealthline.org/news/article/2-million-medi-cal-california-medicaid-asset-test-savings/?utm_campaign=KFF-The-Latest&utm_medium=email&_hsmi=294176208&_hsenc=p2ANqtz-9cDQQSqoOPfbAPGOUQpgChAD1wPI7l4kVa1L-xxsEwSW6XfvAV1pmMouMfT12gLotXkwEJGD_vOHyYuKPcTqRer9qBgQ&utm_content=294176208&utm_source=hs_email
GoFundMe Has Become a Health Care Utility
https://kffhealthnews.org/news/article/gofundme-health-care-funding-hospitals-surprise-bills/?utm_campaign=KFF-The-Latest&utm_medium=email&_hsmi=294176208&_hsenc=p2ANqtz--Kg0vp-Tm7pUUh0EgF6gsTFNLymPnCQQHHytX8wnYxr6kCzTeWU3wnKfFWAoNYHJsgNRnUogdEUTlNexCQ81U3jUMnkQ&utm_content=294176208&utm_source=hs_email
In Fight Over Medicare Payments, the Hospital Lobby Shows Its Strength
By Phil Galewitz and Colleen DeGuzman
FEBRUARY 13, 2024
https://kffhealthnews.org/news/article/medicare-site-neutral-payments-hospital-lobby-fight/?utm_campaign=KFF-The-Latest&utm_medium=email&_hsmi=294176208&_hsenc=p2ANqtz-9oyCR8DTcUVJab-gHuu0oDc3IcXBcxaejuvjc4ScmHi7bxlchQTrEY8VA4szkM1GiZjaedVNwrYraZaNOp1LDaGodd2g&utm_content=294176208&utm_source=hs_email
States Target Health Insurers’ ‘Prior Authorization’ Red Tape
By Bram Sable-Smith
FEBRUARY 12, 2024
https://kffhealthnews.org/news/article/states-health-insurers-prior-authorization-legislation-gold-carding/?utm_campaign=KFF-The-Latest&utm_medium=email&_hsmi=294176208&_hsenc=p2ANqtz-8k3Jj71QCZL77m2cMtrQZa2UmzVwgsxdlKO4rMTv0kCwejoMFJr3x_CIz4FLsToLIQldfaSA3P1RGX6NW-kMZZRXcUKA&utm_content=294176208&utm_source=hs_email
Prior Authorization in Health Insurance: A Needed Tool to Contain Costs or an Excessive Barrier to Needed Care? Fecha y hora22 feb 2024 02:00 p. m.
https://kff-org.zoom.us/webinar/register/6016575551704/WN_MQJ6rvwkSb2SoUV6iKrRLg?utm_campaign=KFF-The-Latest&utm_medium=email&_hsmi=294176208&_hsenc=p2ANqtz-9VYyl9GSrL7W2Ai5asedseLTriezG1YbRN8GPIupWAZqdgJSdVWU1VoSi1954q3ISzbrj7irET660bOs9O8ABiYwECbA&utm_content=294176208&utm_source=hs_email#/registration
Join us for our first Health Wonk Shop of 2024 as we explore the future of prior authorization requirements in health care. The expert panel will discuss why insurers use prior authorization, its impact on patients and providers, and how the new and future regulations may change current practices.
Nearly 1 in 5 consumers with health insurance say their insurer delayed or denied care in the past year due to its requirements for prior authorization, a process through which insurers can require patients to obtain approval in advance before they will agree to cover specific services.
Insurers point to prior authorization as a tool to limit unnecessary and ineffective care, thereby reducing costs. However, the practice is also drawing increased scrutiny amid concerns that it creates unreasonable barriers to patients getting needed care and generates excessive paperwork burdens on doctors and other providers. Last month, federal regulators finalized new rules to govern how insurers use prior authorization in Medicare Advantage, Medicaid, the Children’s Health Insurance Program, and the Affordable Care Act’s federal Marketplace plans, while lawmakers are weighing potential broader legislation.
On Thursday, Feb. 22 at Noon ET, a panel of four experts will join Larry Levitt, KFF’s executive vice president for health policy, for a 45-minute discussion addressing the future of prior authorization requirements in health care. The panel will discuss why insurers use prior authorization, its impact on patients and providers, and how the new regulations may change current practices. They will also examine the potential for further regulatory or legislative actions to address ongoing concerns.
miércoles, 14 de febrero de 2024
National Center for Excellence in Primary Care Research
National Center for Excellence in Primary Care Research: AHRQ’s research to advance primary care infrastructure, delivery and outcomes. The National Center for Excellence in Primary Care Research (NCEPCR) is the intellectual home for primary care research at AHRQ. The NCEPCR is focused on the Nation's primary care system, providing evidence, practical tools, and other resources for researchers and evaluators, clinicians and clinical teams, quality improvement experts, and healthcare decision makers to improve the quality and safety of care. The NCEPCR is committed to listening to and learning from all members of the primary care community, including patients and families.
Mapping AHRQ's 30-Year Investment in Primary Care Research (1990-2020)
Mapping AHRQ's 30-Year Investment in Primary Care Research (1990-2020): This report describes three decades (1990–2020) of AHRQ's primary care research and highlights how that research has impacted delivery of primary care. It details AHRQ's steady investment in research to improve primary care organization, workforce, quality and safety, digital healthcare, finance and cost, and prevention.
Eastern Virginia Medical School Uses, Contributes to AHRQ's Healthcare Simulation Dictionary
Eastern Virginia Medical School Uses, Contributes to AHRQ's Healthcare Simulation Dictionary: Eastern Virginia Medical School (EVMS) in Norfolk, Virginia, uses and contributes to the AHRQ Healthcare Simulation Dictionary, which international simulation experts developed to standardize the growing list of terms in this expanding field. AHRQ partnered with the Society for Simulation in Healthcare to develop the dictionary in order to boost communication and clarity in healthcare teaching, education, assessment, and research.
National Center for Excellence in Primary Care Research
National Center for Excellence in Primary Care Research: AHRQ’s research to advance primary care infrastructure, delivery and outcomes. The National Center for Excellence in Primary Care Research (NCEPCR) is the intellectual home for primary care research at AHRQ. The NCEPCR is focused on the Nation's primary care system, providing evidence, practical tools, and other resources for researchers and evaluators, clinicians and clinical teams, quality improvement experts, and healthcare decision makers to improve the quality and safety of care. The NCEPCR is committed to listening to and learning from all members of the primary care community, including patients and families.
Webinar Series: Strengthening Primary Care Research
Webinar Series: Strengthening Primary Care Research: This series of webinars focuses on how to strengthen AHRQ’s primary research. For recordings of the presentations and slides, reference the webinars.
Making Healthcare Safer IV
Making Healthcare Safer IV: AHRQ’s fourth iteration of Making Healthcare Safer intends to address this issue by publishing evidence-based reviews of patient safety practices and topics as they are completed. This intentional release of updated reviews will aid healthcare organization leaders in prioritizing implementation of evidence-based practices in a timelier way. The report also will help researchers identify where more research is needed in a timelier way and assist policymakers in understanding which patient safety practices have the supporting evidence for promotion.
Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events
Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events: The Agency for Healthcare Research and Quality (AHRQ) Making Healthcare Safer (MHS) reports consolidate information for healthcare providers, health system administrators, researchers, and government agencies about patient safety practices (PSPs) that can improve patient safety across the healthcare system—from hospitals to primary care practices, long-term care facilities, and other healthcare settings.
Deprescribing To Reduce Medication Harms in Older Adults
Deprescribing To Reduce Medication Harms in Older Adults: Deprescribing has the potential to improve multiple aspects of patient safety and quality of care, including by reducing drug burden, ADEs, and morbidity.
Healthcare Worker Implicit Bias Training and Education
Healthcare Worker Implicit Bias Training and Education: In the context of this review, implicit biases are unconscious attitudes and beliefs that may influence behaviors such as nonverbal communication, healthcare worker (HCW) perceptions and clinical assessments about patients, and decisions about patient management.
CAHPS Patient Narrative Item Sets
CAHPS Patient Narrative Item Sets: Learn about CAHPS Patient Narrative Item Sets (Narrative Elicitation Protocols), which are valuable, open-ended questions prompting respondents to tell stories about their healthcare experiences. Narratives help clinicians improve care and engage and inform patients about differences among providers.
CAHPS Clinician & Group Survey
CAHPS Clinician & Group Survey: Read about the CAHPS Clinician & Group Survey (CG-CAHPS), a standardized instrument assessing patients’ experience with healthcare providers and staff in doctors' offices. Results can help improve ambulatory care and equip consumers with comparative information to choose healthcare providers.
Characteristics of Young Adults Aged 18-24 Who Had Ever Used an Electronic Nicotine Product, 2021 Statistical Brief #554 | February 2024 | Anita Soni, PhD, MBA, and Sandra L. Decker, PhD
Characteristics of Young Adults Aged 18-24 Who Had Ever Used an Electronic Nicotine Product, 2021
Statistical Brief #554 | February 2024 | Anita Soni, PhD, MBA, and Sandra L. Decker, PhD
https://meps.ahrq.gov/data_files/publications/st554/stat554.shtml
martes, 13 de febrero de 2024
Atrial Fibrillation 2024
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 1.5-2% of European adults, with an anticipated surge to 9.5% in individuals aged over 65 by 2060. As a primary contributor to stroke, dementia, heart failure, and premature mortality, AF constitutes a significant threat to the expanding elderly demographic and healthcare systems.
This Series of five articles in The Lancet Regional Health - Europe, provides a comprehensive exploration of AF-related themes. It encompasses an evaluation of the potential of AF screening for stroke and embolism prevention, explores emerging links between genetic regulation and pathophysiology, discusses recent advances in comprehending and managing risk factors, outlines current treatment modalities for rate and rhythm control, and elucidates the contemporary approach to stroke prevention.
The esteemed panel of experts contributing to this Series have identified key opportunities for improving AF care. These include the implementation of digital screening, the development of robust methodologies to discern ethnic and racial variations in AF risk, the development of predictive models to accommodate long-term trajectories in risk factors, and a push for greater patient involvement in treatment decision-making processes.
https://www.thelancet.com/series/europe-atrial-fibrillation?dgcid=hubspot_update_feature_lanepeatrialfibrillation24&utm_campaign=update-lanepe&utm_medium=email&_hsmi=293795093&_hsenc=p2ANqtz-9rJCmqnt3OqvJ7X5_8kYbFIc5bX83r2r6Dqd_ee_jpL8t39cc5EtF34vJKJRbexsQHeAdzbUbWOGA7M7tXxdIC9LcxLQ&utm_content=293762779&utm_source=hs_email
lunes, 12 de febrero de 2024
How financially vulnerable are people with medical debt? By Aubrey Winger, Gary Claxton, Matthew Rae Twitter, Anthony Damico, and Shameek Rakshit KFF February 12, 2024
https://www.healthsystemtracker.org/brief/how-financially-vulnerable-are-people-with-medical-debt/?_hsmi=293744663&_hsenc=p2ANqtz--Kmuo-WQUrjLlZAeFkiMjhSrn4jJLAt9JFA_CUNKXIqqHMaoLRM0-Th7cwiGVidL7o72bGeQp1SAFa0RcPKp6SFGDS8A&utm_campaign=KFF-Peterson&utm_medium=email&utm_content=293744663&utm_source=hs_email
CONTACT: Tammie Smith | 202.654.1410 | TammieS@kff.org
A response to your 3 Feb post regarding red-light therapy for myopia
Dear Editor of the Salud Equitativa blog,
On the 3rd of February you reposted an article from STAT News about red-light therapy for the treatment of myopia. My client is the manufacturer of the only red-light therapy device to be licensed and approved for the treatment of myopia in mor than 30 countries around the world. As such we would appreciate an opportunity to rebut some of the inaccurate statements made by Dr. Ostrin in that article.
I hope you will consider posting our letter of response below.
Dear Editor,
Eyerising International would appreciate an opportunity to respond to, and rebut certain claims made in, an article you posted on 3rf February under the headline, “Promising red-light myopia treatment for children is raising safety concerns among experts Annalisa Merelli By Annalisa Merelli Feb. 2, 2024”
The piece was reporting on an article recently published in the Ophthalmic & Physiological Optics (OPO) Journal, titled, “Red light instruments for myopia exceed safety limits”, which was authored by Lisa A. Ostrin and Alexander W. Schill.
Eyerising International has spoken to the Editor-in-Chief of the OPO Journal, and he has agreed to give the company the right of reply to Dr Ostrin’s article and to publish a letter to the editor addressing several of the inaccuracies and misrepresentations in Dr Ostrin’s OPO article.
As the originator of repeat low-level, red light therapy (RLRL) sometimes also called LLRL (low level red light therapy) and the manufacturer of the only red-light myopia management device licensed and approved for the treatment of myopia in multiple countries, Eyerising International would like to address some inaccuracies Dr Ostrin repeated in your article.
Point 1
In the press release, based on only testing two copycat devices in her laboratory Dr Ostrin generalises to all red light devices:
“The safety profiles of red-light laser devices for myopia have not been fully investigated,”
The Eyerising device has been very fully investigated, it has undergone 10 clinical trials and four (4) real world studies, covering 1785 patients, with a cumulative clinical trial use of 9.25 years - with zero
significant adverse events recorded. The device has been used to treat more than 160,000 patients in the real world over the past eight years, and there are currently more than 80,000 daily users. To date, there have only been five (5) cases of significant adverse side effects reported; with no permanent damage recorded.
Point 2
In the press release Dr Ostrin said:
“Based on measurements in our laboratory, it is recommended that clinicians strongly reconsider the use of LLRL therapy for myopia in children until safety standards can be confirmed,”
Numerous countries have established such safety standards and unlike the two copycat devices Dr Ostrin tested in her laboratory the Eyerising device meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and APAC, with several more pending.
1. Eyerising International is ISO 13485:2016 certified by notified body BSI.
2. CE mark as Class IIa medical device
3. MHRA approved Class IIa in UK
4. MedSafe Class IIa in New Zealand
5. TMMDA approved Class IIa in Turkey
6. Australian Register of Therapeutic Goods (ARTG) in Australia
7. Medical Device Authority (MDA) in Malaysia
Point 3
Testing to the wrong standards
Dr Ostrin and her colleague stated in the original OPO article that they tested two devices to the
ANSI Z136.1 standard as the benchmark for their tests. Although they acknowledged that the ANSI Z136.1 standards were developed to protect individuals from accidental exposure to lasers in occupational situations, they did not mention that there is a more recent ANSI standard specifically for ophthalmic instruments.
The ANSI Z80.36 standard specifies fundamental requirements for optical radiation safety for ophthalmic instruments. It applies to all ophthalmic instruments (including current, new, and emerging instruments) that direct optical radiation into, or at the eye. It also applies to those parts of therapeutic or surgical systems that direct optical radiation into, or at the eye for diagnostic, illumination, measurement, imaging, or alignment purposes [2].
It is the ANSI Z80.36-2021 standard, which the FDA required Eyerising to meet and which we obtained.
Point 4
In the article you ran Dr Ostrin said:
“The company behind one of the devices reports that it is already being used to address myopia in over 100,000 pediatric patients.”
As Eyerising International is the only company with an approved product this can only refer to us, although it fails to mention that the Eyerising device has a proven safety record in both clinical trial and real-world settings. The Eyerising device has to be prescribed by an Eye Health professional such as an ophthalmologist or optometrist. It has been used to treat more than 160,000 patients with only five (5) cases of significant adverse side effects reported.
Eyerising International is not just the leading player in the field of LLRL but the only player in the field with a red light device licensed and approved by regulatory authorities in multiple countries for the treatment of myopia. Despite that obvious qualification Dr Ostrin never tested our device and never even requested one of our devices to test. Had she done so we would have been happy to supply one as we have every confidence in its safety record. Despite never testing our device Dr Ostrin referred to it inaccurately several time in her OPO article and by implication by generalising her comments to cover all red light devices for treating myopia, although she only tested two.
In conclusion:
Eyerising International takes our responsibility for ensuring the safety and efficacy of our RLRL therapy device seriously. We remain committed to working closely with healthcare professionals and users to collect and investigate any adverse reactions and to address any potential concerns. Apart from our extensive and on-going clinical trials we always consult the relevant authorities when entering new markets to ensure that our device meets any and all safety standards required by the relevant authorities.
About Eyerising International
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.
Eyerising International’s patented Myopia Management Repeated Low-Level Red–Light (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.
Issued by:
Eyerising International Pty Ltd
2.05 9/11 Claremont St,
South Yarra VIC 3141, Australia
PR@eyerisinginternational.com
References:
Lisa A. Ostrin and Alexander W. Schill. “Red light instruments for myopia exceed safety limits”, OPO January 2024.
ANSI Z80.36-2016
Tian Yu, Xiao Zhigang, Recovery of retinal structural damage after repeated low-intensity red light therapy for high myopia: a case report, CMA.J.CN, August 2023 - https://rs.yiigle.com/cmaid/1471399
John Battersby
Senior Regional Account Director
Bridges M&C Pte Ltd (HQ) | 176 Joo Chiat Road #04-01 Singapore 427447
D: +65 6345 1783 | M: +65 9754 1092 | E: john@bridges-comms.com
Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events
Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events: The Agency for Healthcare Research and Quality (AHRQ) Making Healthcare Safer (MHS) reports consolidate information for healthcare providers, health system administrators, researchers, and government agencies about patient safety practices (PSPs) that can improve patient safety across the healthcare system—from hospitals to primary care practices, long-term care facilities, and other healthcare settings.
One Health Advances - One Health Outlook
https://onehealthadv.biomedcentral.com/
One Health Advances is a peer-reviewed, open access journal committed to publish high-quality research articles, comments, correspondence and reviews describing the advances in public health.
https://onehealthoutlook.biomedcentral.com/
Zoonotic viruses, which transmit diseases between animals and humans, have significant impact on public health, animal health, and the environment. This Collection aims to focus on holistic strategies to prevent, monitor, and manage zoonotic viral diseases.
SOPS Databases
SOPS Databases: The Surveys on Patient Safety Culture (SOPS) Databases serve as a central repository for SOPS survey data.
Workplace Safety Supplemental Item Set for Nursing Home SOPS
Workplace Safety Supplemental Item Set for Nursing Home SOPS: AHRQ is developing a Workplace Safety Supplemental Item Set for the Surveys on Patient Safety Culture™ (SOPS®) Nursing Home Survey.
Nursing Home Survey on Patient Safety Culture
Nursing Home Survey on Patient Safety Culture: The Nursing Home SOPS asks providers and staff for their opinions about the culture of patient safety in their nursing homes.
Value and Efficiency Supplemental Item Set for Hospital SOPS
Value and Efficiency Supplemental Item Set for Hospital SOPS: The Value and Efficiency supplemental items assess efficiency, waste reduction, patient-centeredness, and high quality care at a reasonable cost.
Workplace Safety Supplemental Item Set for Hospital SOPS
Workplace Safety Supplemental Item Set for Hospital SOPS: The SOPS® Workplace Safety Supplemental Items for the Hospital Survey were developed and pilot tested for use with the core SOPS Hospital Survey to help hospitals assess the extent to which their organization’s culture supports workplace safety for providers and staff.
Health IT Patient Safety Supplemental Item Set for Hospital SOPS
Health IT Patient Safety Supplemental Item Set for Hospital SOPS: The Health Information Technology supplemental items assess how Health IT affects patient safety in hospitals.
Hospital Survey on Patient Safety Culture
Hospital Survey on Patient Safety Culture: The Hospital SOPS asks providers and staff for their opinions about the culture of patient safety in their hospitals.
domingo, 11 de febrero de 2024
sábado, 10 de febrero de 2024
Roughly 1 in 5 Adolescents Report Experiencing Symptoms of Anxiety or Depression Although Some Are Getting Mental Health Care, Many Teenagers Say They Are Not Receiving the Therapy They Need Feb 06, 2024Roughly 1 in 5 Adolescents Report Experiencing Symptoms of Anxiety or Depression Although Some Are Getting Mental Health Care, Many Teenagers Say They Are Not Receiving the Therapy They Need Feb 06, 2024
Physician-machine partnerships boost diagnostic accuracy, but bias persists. et al. Nat Med 2024 2 (Posted Feb 09, 2024 10AM)
https://phgkb.cdc.gov/PHGKB/phgHome.action?action=home
From the abstract: "In a large-scale digital experiment on dermatology diagnosis, we found that specialists and generalists achieved diagnostic accuracy of 38% and 19%, respectively. With decision support from a fair deep learning system, the diagnostic accuracy of physicians improved by more than 33%, but the gap in accuracy of generalists widened across skin tones. "